The adjuvant effect of polymuramil, a NOD1 and NOD2 agonist, differs when immunizing mice of different inbred lines with nonstructural hepatitis C virus (Flaviviridae: Hepacivirus)proteins and is synergistically enhanced in combination with pyrogenalum, a TLR4 agonist
Open Access
- 21 September 2023
- journal article
- research article
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 68 (4) , 315-326
Abstract
Introduction. Hepatitis C is a liver disease with high chronicity, the cause of cirrhosis and hepatocarcinoma. The main obstacle to controlling hepatitis C is the lack of vaccines. The aim of the work was to compare the immunogenic activity of nonstructural recombinant proteins NS3, NS4 and NS5B of hepatitis C virus (HCV) as components of a subunit candidate vaccine and to analyze the adjuvant properties of two available commercial drugs, polymuramil and pyrogenalum. Materials and methods. BALB/c, DBA/2J and C57BL/6 mice were immunized with nonstructural proteins without adjuvants or with polymuramyl (NOD1 and NOD2 agonist) and pyrogenalum (TLR-4 agonist). The activity of antibodies was determined in ELISA, the cellular response by antigen-specific lymphocyte proliferation and by production of IFN- in vitro. Results. Recombinant proteins showed different immunogenicity. NS4 induced antibodies more efficiently than NS3 and NS5B. Significant differences were found in the immune response of three inbred lines mice: the level of IFN- in BALB/c and DBA/2J mice induced by NS5B protein was 30 times higher than in C57Bl/6 mice. In contrast, the induction of antibodies in BALB/c mice was lower than in C57Bl/6 and DBA/2J. Polymuramil did not increase the humoral response to NS5B and enhanced the cellular response only in C57BL/6 mice. The combined use of polymuramil with pyrogenalum significantly increased both the humoral and cellular response of mice to all recombinant HCV proteins. Conclusion. Different immunogenic properties and different functions of recombinant non-structural HCV proteins indicate the feasibility of their combined inclusion in subunit vaccines. It was established for the first time that immunization with HCV proteins with a complex adjuvant (polymuramyl + pyrogenalum) has a synergistic effect, significantly exceeding the effect of each of them separately.Keywords
This publication has 44 references indexed in Scilit:
- Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium InfectionInfection and Immunity, 2013
- Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligandsEuropean Journal of Immunology, 2011
- Host Genetic Background Strongly Influences the Response to Influenza A Virus InfectionsPLOS ONE, 2009
- Chronic stimulation of Nod2 mediates tolerance to bacterial productsProceedings of the National Academy of Sciences, 2007
- Development of the system ensuring a high-level expression of hepatitis C virus nonstructural NS5B and NS5A proteinsProtein Expression and Purification, 2006
- Nod1 Detects a Unique Muropeptide from Gram-Negative Bacterial PeptidoglycanScience, 2003
- Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) DetectionJournal of Biological Chemistry, 2003
- Differences in Expression of Toll-Like Receptors and Their Reactivities in Dendritic Cells in BALB/c and C57BL/6 MiceInfection and Immunity, 2002
- Differential production of IL-12 in BALB/c and DBA/2 mice controls IL-4 versus IFN-γ synthesis in primed CD4 lymphocytesInternational Immunology, 1996
- IDentification of helper T cell epitopes of dengue virus E-proteinMolecular Immunology, 1993